News Related to Primary Hypercholesterolemia

Related coverage linked through entity extraction aliases.

NewAmsterdam Pharma reports Q1 results, keeps obicetrapib regulatory and Phase 3 timelines

May 13, 2026

NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.

LIB Therapeutics launches Lerochol in the United States after FDA approval

May 11, 2026

LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.